GE HealthCare delivered revenue growth in Q4 2025 driven by Imaging and Pharmaceutical Diagnostics, while profitability declined year over year due to tariffs and unfavorable mix.

GE HealthCare posted a strong third quarter, driven by 6% organic revenue growth, improved adjusted EBIT margin, and continued strategic investments in innovation and productivity.

GE HealthCare delivered strong Q2 2025 results with $5 billion in revenue and increased profitability. Gains were driven by operational execution, lower tax and interest expense, and strength in radiopharma and imaging orders. The company raised its full-year guidance.

GE HealthCare reported a strong start to 2025 with 4% organic revenue growth and notable profit expansion, supported by robust U.S. demand and operational execution.

GE HealthCare reported 2.17% revenue growth in Q4 2024, reaching $5.319 billion. Strong performance in Advanced Visualization Solutions and Pharmaceutical Diagnostics drove results, alongside improved operating and net margins. Adjusted earnings per share grew 22.88% year-over-year.

GE HealthCare's Q3 2024 results showed a 1% increase in revenue and organic revenue. The company experienced margin expansion and improved earnings per share. They also updated their full-year guidance, raising the low end of adjusted EBIT margin and adjusted EPS expectations.

GE HealthCare's Q2 2024 results showed flat revenues year-over-year but a 1% increase on an organic basis. Net income margin and adjusted EBIT margin both improved. The company updated its full-year guidance for organic revenue growth and adjusted EBIT margin.

GE HealthCare reported a 1% decline in revenues, but organic revenue was approximately flat. Net income margin increased to 8.0%, and adjusted EBIT margin rose to 14.7%. Diluted EPS was $0.81, and adjusted EPS was $0.90. The company reaffirmed its full-year 2024 guidance.

GE HealthCare reported a 5% increase in revenue, with organic revenue growth of 6%. Net income was $375 million, and adjusted EBIT was $744 million. The company raised the low end of its full-year Adjusted EPS guidance range.

GE HealthCare's Q2 2023 results showed a 7% increase in revenue, with organic revenue growth of 9%. Net income was $418 million, and adjusted EBIT was $711 million. The company raised its full-year guidance for organic revenue growth and adjusted EPS.

GE HealthCare reported a revenue of $4.7 billion, an 8% increase year-over-year. Net income attributable to GE HealthCare was $372 million, and adjusted EPS was $0.85. The company reaffirmed its full-year 2023 guidance, expecting 5% to 7% organic revenue growth.

GE HealthCare reported an 8% increase in revenues, reaching $4.9 billion, and a net income of $554 million for Q4 2022. The company's performance was driven by growth in Imaging, Patient Care Solutions (PCS), and Ultrasound, with a book-to-bill ratio of 1.07. GE HealthCare reaffirmed its 2023 guidance and introduced 2023 Adjusted EPS guidance.